Jonathan Schelfhout

Efficacy and safety of gefapixant, a P2X3 receptor antagonist, in refractory chronic cough and unexplained chronic cough (COUGH-1 and COUGH-2): results from two double-blind, randomised, parallel-group, placebo-controlled, phase 3 trials

Lorcan McGarvey, Surinder S. Birring, Alyn H. Morice et al. · The Lancet · 2022 · 312 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +11

Validation of a visual analog scale for assessing cough severity in patients with chronic cough

Allison Martin Nguyen, Elizabeth D. Bacci, Margaret Vernon et al. · Therapeutic Advances in Respiratory Disease · 2021 · 115 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +15

Prevalence and Burden of Chronic Cough in the United States

Eli O. Meltzer, Robert S. Zeiger, Peter V. Dicpinigaitis et al. · The Journal of Allergy and Clinical Immunology In Practice · 2021 · 93 citations

Medicine, Preventive Medicine, Public Health Practice +13

Leicester Cough Questionnaire validation and clinically important thresholds for change in refractory or unexplained chronic cough

Allison Martin Nguyen, Jonathan Schelfhout, David Muccino et al. · Therapeutic Advances in Respiratory Disease · 2022 · 76 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +15

Disease burden and quality of life of patients with chronic cough in Japan: a population-based cross-sectional survey

Takekazu Kubo, Keisuke Tobe, Kotoba Okuyama et al. · BMJ Open Respiratory Research · 2021 · 60 citations · Full text

Pharmacy, Health Sciences, Health Assessment +16